The global veterinary biologics market is poised for consistent growth, expected to reach USD 3.51 billion by 2030 from USD 2.72 billion in 2025, registering a compound annual growth rate (CAGR) of 5.2% during the forecast period (2025–2030). The market’s upward trajectory is being fueled by multiple factors, including the rising incidence of chronic diseases in animals, the increasing adoption of companion animals, and growing investments in innovative biologic therapies.
Evolving Landscape of Veterinary Care
The veterinary healthcare sector is witnessing a paradigm shift, with biologics emerging as a cornerstone of advanced treatment. Chronic and recurring conditions—such as atopic dermatitis, osteoarthritis, and infectious diseases—are increasingly common among companion animals, necessitating effective and targeted therapies.
A number of biologic products, such as Cytopoint, Librela, Solensia, Gilvetmab, and Canine Parvovirus Monoclonal Antibody (CPMA), have demonstrated strong clinical efficacy, transforming treatment outcomes in veterinary medicine. These therapies provide longer-lasting relief with fewer side effects compared to traditional pharmaceuticals, significantly improving the quality of life for animals.
Moreover, technological advancements are enhancing diagnostics, treatment precision, and patient monitoring. The rise of teledermatology, coupled with digital health platforms, is expanding access to specialized veterinary care, particularly in remote or underserved regions.
Growing pet owner awareness, broader pet insurance coverage, and increased research and development (R&D) investments are further propelling market innovation, paving the way for next-generation biologics that address complex and chronic health conditions.
Monoclonal Antibodies Lead Product Innovation
“By product type, the monoclonal antibodies segment is expected to grow at the fastest rate in the global veterinary biologics market during the forecast period.”
Monoclonal antibodies (mAbs) are revolutionizing veterinary healthcare due to their targeted mechanism of action and high efficacy. These biologics work by precisely targeting pathogens or toxins, offering a more selective and effective approach than conventional treatments such as antibiotics.
In livestock management, monoclonal antibodies are invaluable for rapid immune support, helping reduce disease morbidity and improve productivity. Their role in mitigating antimicrobial resistance (AMR) aligns with global initiatives promoting sustainable animal farming and responsible antimicrobial use.
The growing demand for biologic-based disease prevention and treatment reflects a major shift in veterinary medicine — from symptom management to molecular-level intervention.
Dermatology Emerges as a Dominant Application
“By application, the dermatology segment accounted for the largest share of the global veterinary biologics market.”
The dermatology segment holds a dominant position in the veterinary biologics landscape, driven by the rising incidence of skin disorders such as allergies, bacterial infections, fungal diseases, and parasitic infestations in both companion and livestock animals.
As pet ownership grows worldwide, so does the demand for high-quality animal healthcare. Biologics for dermatological conditions—including vaccines, immunotherapies, and monoclonal antibodies—offer long-lasting relief and improved treatment outcomes. Their ability to minimize adverse effects while maintaining therapeutic efficacy makes them particularly appealing to veterinarians and pet owners alike.
Further, increasing healthcare expenditure, the proliferation of veterinary clinics, and the expansion of specialized dermatology care are accelerating this segment’s growth. With more targeted and durable biologic formulations being introduced, the dermatology segment is expected to maintain its leading market share in the coming years.
Regional Outlook: North America at the Forefront
“By region, the North America region accounted for the largest share during the forecast period.”
North America continues to dominate the veterinary biologics market, driven by a rising pet population, increased awareness of animal health, and higher spending on veterinary care. The region’s robust healthcare infrastructure, extensive R&D activities, and strong presence of global market leaders further strengthen its market position.
Interestingly, while North America leads in adoption, Asia-Pacific countries such as China and India are emerging as high-potential markets due to large livestock populations and growing demand for meat, milk, and animal-derived products. The modernization of livestock management and government initiatives to reduce disease outbreaks are creating favorable conditions for biologic adoption in these regions.
Key Market Players
The veterinary biologics market is characterized by a mix of established global leaders and innovative emerging companies. Prominent players include:
- Zoetis Services LLC (US)
- IDEXX Laboratories (US)
- Elanco Animal Health (US)
- Merck & Co., Inc. (US)
- Thermo Fisher Scientific Inc. (US)
- Boehringer Ingelheim International GmbH (Germany)
- Neogen Corporation (US)
- Bio-Rad Laboratories, Inc. (US)
- ImmuCell Corporation (US)
- Innovative Diagnostics (France)
These companies are actively investing in biologic R&D, strategic collaborations, and regulatory approvals to expand their product portfolios. Their focus on innovation—particularly in monoclonal antibodies and immunotherapies—underscores the market’s shift toward precision veterinary medicine.
Conclusion: A Promising Future for Veterinary Biologics
The global veterinary biologics market is entering a transformative phase. As the demand for safe, effective, and targeted therapies continues to rise, biologics are set to become integral to modern veterinary care. With strong industry backing, expanding applications, and ongoing scientific innovation, the sector is well-positioned for sustained growth through 2030 and beyond.
From improving animal welfare to promoting sustainable livestock practices, veterinary biologics represent the future of animal health—where technology, science, and compassion converge to create lasting impact.